Articles related to BILE DUCT CANCER

Take part in an engaging multidisciplinary discussion on the evolving dynamics of hepato-pancreatico-biliary cancers. Discover, learn, and prepare to integrate these new strategies into your clinical practice.

The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.

In this case-control registry study of 63,828 patients with 14 common cancer types and 37,086 controls, pathogenic variants in BRCA1 were associated with biliary tract cancer, BRCA2 was associated with esophageal cancer, and combined BRCA1/2, with gastric cancer.

The BILCAP study established capecitabine as the adjuvant standard of care for patients after curatively resected biliary tract cancer (BTC). This publication presents the long-term data of that study. In the intention-to-treat analysis, the median OS was 49.6 months in the capecitabine group compared with 36.1 months in the observation group.

This open-label, randomized phase II-III study of 191 patients with locally advanced or metastatic BTC compared triplet therapy of oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), with doublet therapy consisting of cisplatin and gemcitabine (CISGEM). Triplet therapy did not outperform doublet therapy in this study.